Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours

Authors: Ellis, P.A., Norman, A., Hill, A., O'Brien, M.E.R., Nicolson, M., Hickish, T. and Cunningham, D.

Journal: European Journal of Cancer

Volume: 31

Issue: 10

Pages: 1594-1598

ISSN: 0959-8049

DOI: 10.1016/0959-8049(95)00323-B

Abstract:

Hepatobiliary tumours are rare, often present late and have a poor prognosis, with no current effective systemic therapy available. This study aimed to evaluate the activity and toxicity of epirubicin, cisplatin and continuous infusional 5-fluorouracil (5-FU) (ECF) in patients with these tumours. From March 1991 to November 1993, 25 patients with advanced biliary tumours and 7 with hepatoma were treated with epirubicin 50 mg/m2 and cisplatin 60 mg/m2 intravenously (i.v.) day 1, each given every 21 days and 5-FU 200 mg/m2/day given as a continuous 24 h i.v. infusion throughout the treatment course. 8 of the 20 (40%) evaluable patients with biliary tumours responded. Median duration of response was 10 months. 2 of the 7 (29%) patients with hepatoma responded. The regimen was well tolerated with minimal haematological and non-haematological toxicity. This novel regimen is active in advanced hepatobiliary tumours. © 1995.

Source: Scopus

Preferred by: Tamas Hickish

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.

Authors: Ellis, P.A., Norman, A., Hill, A., O'Brien, M.E., Nicolson, M., Hickish, T. and Cunningham, D.

Journal: Eur J Cancer

Volume: 31A

Issue: 10

Pages: 1594-1598

ISSN: 0959-8049

DOI: 10.1016/0959-8049(95)00323-b

Abstract:

Hepatobiliary tumours are rare, often present late and have a poor prognosis, with no current effective systemic therapy available. This study aimed to evaluate the activity and toxicity of epirubicin, cisplatin and continuous infusional 5-fluorouracil (5-FU) (ECF) in patients with these tumours. From March 1991 to November 1993, 25 patients with advanced biliary tumours and 7 with hepatoma were treated with epirubicin 50 mg/m2 and cisplatin 60 mg/m2 intravenously (i.v.) day 1, each given every 21 days and 5-FU 200 mg/m2/day given as a continuous 24 h i.v. infusion throughout the treatment course. 8 of the 20 (40%) evaluable patients with biliary tumours responded. Median duration of response was 10 months. 2 of the 7 (29%) patients with hepatoma responded. The regimen was well tolerated with minimal haematological and non-haematological toxicity. This novel regimen is active in advanced hepatobiliary tumours.

Source: PubMed

EPIRUBICIN, CISPLATIN AND INFUSIONAL 5-FLUOROURACIL (5-FU) (ECF) IN HEPATOBILIARY TUMORS

Authors: ELLIS, P.A., NORMAN, A., HILL, A., OBRIEN, M.E.R., NICHOLSON, M., HICKISH, T. and CUNNINGHAM, D.

Journal: EUROPEAN JOURNAL OF CANCER

Volume: 31A

Issue: 10

Pages: 1594-1598

ISSN: 0959-8049

DOI: 10.1016/0959-8049(95)00323-B

Source: Web of Science (Lite)

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.

Authors: Ellis, P.A., Norman, A., Hill, A., O'Brien, M.E., Nicolson, M., Hickish, T. and Cunningham, D.

Journal: European journal of cancer (Oxford, England : 1990)

Volume: 31A

Issue: 10

Pages: 1594-1598

eISSN: 1879-0852

ISSN: 0959-8049

DOI: 10.1016/0959-8049(95)00323-b

Abstract:

Hepatobiliary tumours are rare, often present late and have a poor prognosis, with no current effective systemic therapy available. This study aimed to evaluate the activity and toxicity of epirubicin, cisplatin and continuous infusional 5-fluorouracil (5-FU) (ECF) in patients with these tumours. From March 1991 to November 1993, 25 patients with advanced biliary tumours and 7 with hepatoma were treated with epirubicin 50 mg/m2 and cisplatin 60 mg/m2 intravenously (i.v.) day 1, each given every 21 days and 5-FU 200 mg/m2/day given as a continuous 24 h i.v. infusion throughout the treatment course. 8 of the 20 (40%) evaluable patients with biliary tumours responded. Median duration of response was 10 months. 2 of the 7 (29%) patients with hepatoma responded. The regimen was well tolerated with minimal haematological and non-haematological toxicity. This novel regimen is active in advanced hepatobiliary tumours.

Source: Europe PubMed Central